Comparison of losartan with ACE inhibitors and dihydropyridine calcium channel antagonists: A pilot study of prescription-event monitoring in Japan

Drug Safety

Volumn 25, Issue 11, 2002, Pages 811-821

  Samizo, K ^a   Kawabe, E ^a   Hinotsu, S ^a   Sato, T ^a   Kageyama, S ^b   Hamada, C ^c   Ohashi, Y ^d   Kubota, K ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKYO UNIVERSITY OF SCIENCE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; PHOSPHOTRANSFERASE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHMA; BOOK; CALCULATION; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DATA ANALYSIS; DRUG CONTROL; DRUG INDUCED DISEASE; DRY SKIN; EDEMA; FEMALE; FOLLOW UP; HEADACHE; HEART PALPITATION; HOSPITAL; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; INFORMATION PROCESSING; INSOMNIA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARMACIST; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RASH; RHINITIS; STATISTICAL SIGNIFICANCE;

EID: 0036398302     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200225110-00005     Document Type: Article

References (17)

1. Kubota K. A design for prescription-event monitoring in Japan (J-PEM). Pharmacoepidemiol Drug Saf 1999; 8: 447-56
2. Kubota K, Kawabe E, Hinotsu S, et al. Pilot study of prescription-event monitoring in Japan comparing troglitazone with alternative oral hypoglycaemics. Eur J Clin Pharmacol 2001; 56: 831-8
3. Tanaka K, Morita Y, Kawabe E, et al. Drug use investigation (DUI) and prescription-event monitoring in Japan (J-PEM). Pharmacoepidemiol Drug Saf 2001; 10: 653-8
4. Kubota K. Prescription-event monitoring in Japan (J-PEM). Drug Saf 2002; 25 (6): 441-4
5. Pylypchuc GB. ACE-inhibitor-versus angiotensin II blocker-induced cough and angioedema. Ann Pharmacother 1998; 32: 1060-6
6. Conigliaro RL, Gleason PP. Losartan-induced cough after lisinopril therapy. Am J Health Syst Pharm 1999; 56: 914-5
7. Dicpinigaitis PV, Thomas SA, Sherman MB, et al. Losartan-induced bronchospasm. J Allergy Clin Immunol 1996; 98: 1128-30
8. Mann RD, Mackay F, Pearce G, et al. Losartan: a study of pharmacovigilance data on 14522 patients. J Hum Hypertens 1999; 13: 551-7
9. Makay FJ, Pearce GL, Mann RD. Cough and angiotensin II receptor antagonists: cause or confounding? Br J Clin Pharmacol 1999; 47: 111-4
10. Mann RD. Prescription-even monitoring. In: Strom BL, editor. Pharmacoepidemiology. 3rd ed. New York (NY): John Wiley & Sons, 2000: 231-46
11. Yokotsuka M, Aoyama M, Kubota K. The use of medical dictionary for regulatory activities terminology (MedDRA) in prescription-event monitoring in Japan (J-PEM). Int J Med Inf 2000; 57: 139-53
12. Kalbfleish JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley, 1980
13. Nu-lotan package insert [Japanese]. Ban-yu Pharmaceutical Co., Ltd., Tokyo, Japan. Feb 2001
14. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-9
15. Kubota K, Inman WHW. Terminology in prescription-event monitoring. Eur J Clin Pharmacol 1994; 46: 497-500
16. Inman WHW. Postmarketing surveillance of adverse drug reactions in general practice. II: prescription-event monitoring at the University of Southampton. BMJ 1981; 282: 1216-7
17. Inman WHW, Rawson NSB, Wilton LV. Prescription-event monitoring. In: Inman WHW, editor. Monitoring for drug safety. 2nd ed. Lancaster: MTP Press, 1985: 213-35